1. Use of recombinant granulocyte-macrophage colony stimulating factor in the Brazil radiation accident.
- Author
-
Butturini A, De Souza PC, Gale RP, Cordiero JM, Lopes DM, Neto C, Cunha CB, De Souza CE, Ho WG, and Tabak DG
- Subjects
- Acute Disease, Adolescent, Adult, Agranulocytosis etiology, Agranulocytosis mortality, Brazil, Child, Colony-Stimulating Factors adverse effects, Drug Evaluation, Environmental Exposure, Equipment Contamination, Female, Food Contamination, Radioactive, Granulocyte-Macrophage Colony-Stimulating Factor, Growth Substances adverse effects, Humans, Male, Middle Aged, Radiation Dosage, Radiation Injuries etiology, Radiation Injuries mortality, Radioactive Waste adverse effects, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Time Factors, Accidents, Agranulocytosis drug therapy, Cesium Radioisotopes adverse effects, Colony-Stimulating Factors therapeutic use, Growth Substances therapeutic use, Radiation Injuries drug therapy
- Abstract
8 patients with bone marrow failure after a caesium-137 radiation accident were treated with recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF). The 7 who were evaluable had prompt increases in granulocytes and bone marrow cellularity. 2 patients died of radiation toxicity and haemorrhage and 2 of bacterial sepsis acquired before the start of rHuGM-CSF treatment. 4 patients survive, including 2 who were treated early and never became infected. This therapeutic approach to radiation-induced granulocytopenia may therefore be useful after radiation and nuclear accidents.
- Published
- 1988
- Full Text
- View/download PDF